Abstract: The present invention relates to the fields of cell biology, molecular biology, and medicine. More specifically, the invention is directed to generating cardiomyocyte cells from non-cardiomyocyte cells by enhancing the activation of the Wnt/?-catenin signaling pathway. The cardiomyocyte cells that are generated in the present invention are then used as cardiac disease therapy.

Abstract: A liquid crystal display panel is provided with an array circuit substrate, a counter substrate, and a liquid crystal material held between the substrates. Signal line terminals are disposed at an edge portion of the circuit array substrate. A flexible printed circuit board includes a base film and a signal line layer put along the base film. The signal line layer of the flexible printed circuit board is thermally pressure-contacted to the terminals of the circuit array substrate through an electrically anisotropic conductive film. The anisotropic conductive film has a connecting portion and an extra portion extending from the connecting portion. Such thermally pressure-contacting is carried out by applying a hot press tool to the flexible printed circuit board. A support member is formed out of the connecting portion of the anisotropic conductive film at the edge portion of the array substrate.

Abstract: A restriction enzyme is obtained by cultivating a strain of Brevibacterium linens and recovering the restriction enzyme.

Abstract: An antibiotic R106 represented by the general formula I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.-HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: There are provided R106 compounds represented by the following general formula (I): ##STR1## wherein: A.sub.1 is Phe, o-FPhe, m-FPhe, or Tyr;A.sub.2 is MePhe, o-FMePhe, m-FMePhe, MeTyr, Sar, MeSery, or .beta.-oxoMePhe;A.sub.3 is Pro, 4Hyp, or SPro;A.sub.4 is allo-Ile or Nle;A.sub.5 is Leu or Nva;A.sub.6 is .beta.-HOMeVal or Sar;excluding those wherein A.sub.1 is Phe and A.sub.2 is MePhe and A.sub.3 is Pro and A.sub.4 is allo-Ile and A.sub.5 is Leu and A.sub.6 is .beta.-HOMeVal (SEQ ID No. 4), which are useful as therapeutic agents for fungal infection.

Abstract: An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.-HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: An agent for relieving radiogenic or drug-induced side effects, characterized by comprising a spergualin derivative of the following formula (I):NH.sub.2 --C(.dbd.NH)--NH--R.sub.1 --R.sub.2 --CONH--R.sub.3 --CONH--(CH.sub.2).sub.4 --NH--(CH.sub.2).sub.3 --NH--Xwherein R.sub.1 represents --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 ##STR1## R.sub.2 represents --(CH.sub.2).sub.2 -- or --CH.dbd.CH--, R.sub.3 represents --(CH(OH)--CH(OMe)--, --CH.sub.2 -- or --(CH.sub.2).sub.m --CH(OH)--(CH.sub.2).sub.n -- (m represent an integer of 0,1 or 2 and n represents an integer of 1 or 2)X represents a hydrogen atom or a group formed by removing a hydroxyl group from a carboxyl group of an amino acid,or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: N-[4-(3-Aminopropyl)aminobutyl]-2-(.omega.-guanidino-fatty acid-amido)-2-substituted-ethanamides represented by the general formula ##STR1## wherein Y represents --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH or ##STR2## R represents a hydrogen atom, an alkyl group of 1 to 4 carbon atoms which may have a hydroxyl group as substituent, or a benzyl group, and n is an integer of from 1 to 8, provided that when Y is ##STR3## and n is 4, R represents the groups other than the hydrogen atom; salt thereof having antitumor activity in experimental animal tumors and a process for the preparation thereof is provided.

Abstract: The present invention relates to novel Spergualin-related compounds represented by the general formula [I] ##STR1## (wherein X is ##STR2## R is --H or --CH.sub.2 OH; R.sub.1 is --H, ##STR3## R.sub.2 is a residue obtained by removing, from an amino acid or peptide, the hydroxyl group of the carboxyl group and, when R.sub.1 is a group other than --H, R.sub.2 is same as R.sub.1), or a pharmacologically acceptable salt thereof. Said compounds or salts thereof have an immuno-modulating action.

Abstract: 2-amino-2-deoxy-D-mannitol is produced from a microorganism strain of the genus Streptomyces or a mutant strain thereof in improved yields and purity.

Abstract: The present invention relates to a stable medical composition for injection containing (1) a Spergualin of the formula: ##STR1## [wherein R is ##STR2## (wherein R' is a lower alkyl group having 1 to 4 carbon atoms), ##STR3## or a salt thereof and (2) at least one stabilizer selected from the group consisting of mannitol, maltose, dextran, lactose, cyclodextrin, gelatin, chondroitin sulfate, and human serum albumin; when R is ##STR4## mannitol is excepted. A spergualin is useful as cancer control agents and immunomodulators.

Abstract: The present invention relates to an immunosuppressing method which comprises administering a spergualin-related compound represented by the following formula ##STR1## (wherein R.sub.1 is --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 --, ##STR2## R.sub.2 is --(CH.sub.2).sub.2 -- or --CH.dbd.CH--; and R.sub.3 is ##STR3## or pharmacologically acceptable salts thereof in an effective amount to a warm-blood animal.

Abstract: This invention relates to method for suppressing a transplantation immunity and treating an allergic disease and an autoimmune disease in a mammal which comprises administering spergualin or a pharmaceutically acceptable salt thereof in effective amount to the said mammal.

Abstract: A compound of the formula (I): ##STR1## in which: is a single bond or a double bond,X is hydrogen or hydroxy,n is 0 or 1,Z is ##STR2## when in ring B is a double bond, and, when in ring B is a single bond, Z is wherein W is hydrogen, lower acyl, unsubstituted arylcarbonyl, lower alkyl or substituted arylcarbonyl.These compounds are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to a stable medical composition for injection containing (1) a Spergualin of the formula: ##STR1## [wherein R is ##STR2## --(CH.sub.2).sub.6 --, --(CH.sub.2).sub.4 --CH.dbd.CH--, ##STR3## (wherein R' is a lower alkyl group having 1 to 4 carbon atoms), --(CH.sub.2).sub.8 --, or ##STR4## or a salt thereof and (2) at least one stabilizer selected from the group consisting of mannitol, maltose, dextran, lactose, cyclodextrin, gelatin, chondroitin sulfate, and human serum albumin; when R is ##STR5## mannitol is expected. A spergualin is useful as cancer control agents and immunomodulators.

Abstract: The feature of the present invention is a process for preparing compounds represented by general formula (Ia) described below: ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are as defined in formula (I) and R.sub.10 represents a lower alkyl group, or acid salts thereof, which process is characterized by using the guanidylfungins (II) as raw materials, reacting these guanidylfungins with alcohols (III) in the presence of an acid catalyst, and then hydrolyzing the malonic acid monoester (IV).

Abstract: The novel compound N-[(3-aminoproypl)aminobutyl]-Z-(F-guandino-3-hydroxyheptanamido)-2-methox yethanamide or a pharmaceutically acceptable salt thereof which has antitumor activity in experimental animals.

Abstract: Glyoxylylspermidine, an intermediate for 15-deoxyspergualin-related compounds, is prepared in an oxidative cleavage reaction.

Abstract: The invention relates to Spergualin-related compounds of the formula: ##STR1## (wherein R.sub.1 is a lower alkylene group which may be substituted by a hydroxymethyl group; X is a hydrogen atom or a halogen atom; m and n are each 0 or an integer of 1 to 5) and salts thereof and a process for producing the same.